Global Dyslipidemia Drugs Market 2017-2021

Overview of the global dyslipidemia drugs market

Technavio’s market research report predicts that the global dyslipidemia drugs market will grow at a CAGR of above 5% during the forecast period. The increasing risk of cardiovascular disease (CVDs) is the primary driver for the market’s growth. Elevated cholesterol levels account for nearly one-third of the total ischemic heart diseases and persist as a substantial cause of ischemic heart diseases and strokes in emerging countries such as India and China. Thus, the cardiovascular risk management guidelines set by authorities such as the American College of Cardiology and American Heart Association acknowledge the decreasing the blood cholesterol as a prime factor in cutting down on the cardiovascular risks. This, in turn, drives the cholesterol maintaining drugs to avoid CVDs risk and boosting the sales of the drugs market.

One of the latest trends that will gain traction in the global dyslipidemia drugs market is the increasing use of statins. Described as the best effective dyslipidemia drugs to lower heart attacks risks, the use of statins is also recommended to manage atherosclerotic CVDs. Moreover, based on the guidelines of adult treatment panel (ATPs), four treatment groups have been recognized for statins, two are suggested based on the use of high-intensity statins in individuals with recognized atherosclerotic CVD and other two on moderate-intensity statin therapy and low-intensity statin therapy.

Competitive analysis and key vendors

With the presence of numerous small and larger vendors, the global dyslipidemia drugs market is largely competitive. Competition is observed from the regional players globally, and there are numerous new manufacturers entering the market. Moreover, companies like Amgen, HanAll BioPharma, Kowa Pharmaceuticals, CJ HealthCare, Catabasis Pharmaceuticals, JW Pharmaceuticals, and Esperion Pharmaceuticals are expected to enter the market over the next four years.

Key vendors in the market are:

• AstraZeneca
• Merck
• Pfizer
• Sanofi

Other prominent players include Alnylam Pharmaceuticals, Amarin Corporation,  Amgen, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis, Cipla, CJ HealthCare, CKD Bio, Daewoong Pharmaceutical, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, JW Pharmaceuticals, Kadmon Pharmaceuticals, and Lupin Pharmaceuticals.

Segmentation by drug class and analysis of the dyslipidemia drugs market

• Statins
• Cholesterol absorption inhibitors
• Dyslipidemia injectable

During 2016, the global stains market dominated the drug class segment in the global dyslipidemia drugs market and is expected to continue the domination during the forecast period. Factors like the availablility of a wide range of drugs and the introduction of new guidelines announced by the Adult Treatment Panel IV are expected to result in the segment’s growth over the next four years.

Geographical segmentation and analysis of the dyslipidemia drugs market

• Americas
• APAC
• EMEA

In terms of geography, the Americas led the global dyslipidemia drugs market during 2016 and is foreseen to continue the domination over the next four years. North America is the main contributor for the region’s growth and the rise in patient pool due to changes in the American Heart Association guidelines for the treatment of abnormal cholesterol levels drives the growth. Moreover, the rising occurrence of diseases leading to hypercholesterolemia, stiff pipeline of novel molecules, and rising cholesterol disorders propel the region’s growth.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global dyslipidemia drugs market?
• What are the key market trends impacting the global dyslipidemia drugs market?
• What are the challenges to market growth?
• Who are the key vendors in the global dyslipidemia drugs market?
• What are the market opportunities and threats faced by the vendors in the global dyslipidemia drugs market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global dyslipidemia drugs market?

Technavio also offers customization on reports based on specific client requirement.

Related reports

• Global Muscle Relaxant Drugs Market 2017-2021
• Global Lifestyle Drugs Market 2017-2021
• Global Epilepsy Drugs Market 2016-2020